Show simple item record

dc.contributor.authorAtkins, J. L.
dc.contributor.authorPilling, L. C.
dc.contributor.authorMasoli, Jane A.
dc.contributor.authorMelzer, David
dc.identifier.citationAtkins JL et al. Association of Hemochromatosis HFE p.C282Y Homozygosity With Hepatic Malignancy. JAMA. 2020 Nov 24;324(20):2048-2057.en_US
dc.description.abstractImportance: Hereditary hemochromatosis is predominantly caused by the HFE p.C282Y homozygous pathogenic variant. Liver carcinoma and mortality risks are increased in individuals with clinically diagnosed hereditary hemochromatosis, but risks are unclear in mostly undiagnosed p.C282Y homozygotes identified in community genotyping. Objective: To estimate the incidence of primary hepatic carcinoma and death by HFE variant status. Design, setting, and participants: Cohort study of 451 186 UK Biobank participants of European ancestry (aged 40-70 years), followed up from baseline assessment (2006-2010) until January 2018. Exposures: Men and women with HFE p.C282Y and p.H63D genotypes compared with those with neither HFE variants. Main outcomes and measures: Two linked co-primary outcomes (incident primary liver carcinoma and death from any cause) were ascertained from follow-up via hospital inpatient records, national cancer registry, and death certificate records, and from primary care data among a subset of participants for whom data were available. Associations between genotype and outcomes were tested using Cox regression adjusted for age, assessment center, genotyping array, and population genetics substructure. Kaplan-Meier lifetable probabilities of incident diagnoses were estimated from age 40 to 75 years by HFE genotype and sex. Results: A total of 451 186 participants (mean [SD] age, 56.8 [8.0] years; 54.3% women) were followed up for a median (interquartile range) of 8.9 (8.3-9.5) years. Among the 1294 male p.C282Y homozygotes, there were 21 incident hepatic malignancies, 10 of which were in participants without a diagnosis of hemochromatosis at baseline. p.C282Y homozygous men had a higher risk of hepatic malignancies (hazard ratio [HR], 10.5 [95% CI, 6.6-16.7]; P < .001) and all-cause mortality (n = 88; HR, 1.2 [95% CI, 1.0-1.5]; P = .046) compared with men with neither HFE variant. In lifetables projections for male p.C282Y homozygotes to age 75 years, the risk of primary hepatic malignancy was 7.2% (95% CI, 3.9%-13.1%), compared with 0.6% (95% CI, 0.4%-0.7%) for men with neither variant, and the risk of death was 19.5% (95% CI, 15.8%-24.0%), compared with 15.1% (95% CI, 14.7%-15.5%) among men with neither variant. Among female p.C282Y homozygotes (n = 1596), there were 3 incident hepatic malignancies and 60 deaths, but the associations between homozygosity and hepatic malignancy (HR, 2.1 [95% CI, 0.7-6.5]; P = .22) and death (HR, 1.2 [95% CI, 0.9-1.5]; P = .20) were not statistically significant. Conclusions and relevance: Among men with HFE p.C282Y homozygosity, there was a significantly increased risk of incident primary hepatic malignancy and death compared with men without p.C282Y or p.H63D variants; there was not a significant association for women. Further research is needed to understand the effects of early diagnosis and treatment.en_US
dc.rightsCopyright 2020 American Medical Association. All Rights Reserved.en_US
dc.subjectAlanine Transaminaseen_US
dc.subjectAspartate Aminotransferasesen_US
dc.subjectBiological Specimen Banksen_US
dc.subjectCohort Studiesen_US
dc.subjectGenotyping Techniquesen_US
dc.subjectLiver Neoplasmsen_US
dc.subjectSex Factorsen_US
dc.subjectWessex Classification Subject Headings::Eldery care.en_US
dc.subjectWessex Classification Subject Headings::Public health. Health statistics. Occupational health. Health educationen_US
dc.titleAssociation of Hemochromatosis HFE p.C282Y Homozygosity With Hepatic Malignancyen_US
dc.typeJournal Articleen_US
dc.description.fundingThis research was funded by the UK Medical Research Council award MR/S009892/1 (Dr Melzer), which supports Dr Atkins. Drs Melzer and Pilling are supported by the University of Exeter Medical School and, in part, by the University of Connecticut School of Medicine. Dr Masoli is supported by National Institute for Health Research Doctoral Research Fellowship DRF-2014-07-177. Input from Dr Kuo was supported by the University of Connecticut.en_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record